In September 2024, Protavio proudly announced its official certification as an Olink Service Provider by Olink Proteomics, underscoring the company’s dedication to advancing proteomic research and enhancing clinical diagnostics.
As part of its Olink certification process and dedication to excellence, Protavio has also successfully completed the Olink Concordance Test for Explore HT analysis, which benchmarked data quality against Olink’s AS Uppsala facility. Protavio achieved outstanding results in key metrics including detectability and coefficient of variance (CV). This accomplishment highlights Protavio’s robust technical capabilities and commitment to maintaining superior standards.
Olink Proteomics stands at the forefront of protein biomarker discovery and development with its innovative proximity extension assay (PEA) technology. This advanced method enables high-throughput, multiplexed protein analysis by utilizing proximity probes linked to unique DNA oligonucleotides. When these probes bind to target proteins, they form double-stranded DNA molecules that are amplified and quantified through real-time PCR or Next-Generation Sequencing (NGS). This process ensures precise and scalable protein quantification, enabling researchers to analyze over 5,700 proteins simultaneously if they choose the Olink Explore HT platform.
Protavio’s certification highlights its specialized expertise in multiplex proteomics and its robust Discovery, Development, and Manufacturing (DDM) pipeline. By integrating Olink’s Explore platform with Luminex’s advanced In Vitro Diagnostic (IVD) development and Good Manufacturing Practice (GMP) manufacturing processes, Protavio is uniquely positioned to offer end-to-end solutions for biomarker discovery and assay development for multiplex diagnostics.
With commitment to innovation and quality, Protavio empowers researchers to translate biomarker discoveries into diagnostic tools that enhance patient care and drive scientific progress. By adhering to stringent standards such as ISO13485, IVDR, GMP, and FDA guidelines, Protavio ensures that each biomarker discovery can be accurately translated into reliable multiplex products. These high-quality assays are essential for disease diagnosis and prognosis, facilitating the seamless transition from research to clinical application.